The deployment of drug-eluting stems (DES) to heat bare-metal stem restenosis
[in-stent restenosis (ISR)] has become routine practice, with a consequential decline in the use of
inhacoronaiy brachytherapy (ICBT). However, them are concerns as to the long-term safety profile
ofDES, particularly in terms of late stemthrombosis. In addition, an appropriate treatment strategy
for stenosiswithinDEShas not been developed. The aimofthis studywas to examine the efficacy of
best treatmentwith ICBT for ISR in patients at high risk for fiiture recurrence. |
